Two OTC CGMs Cleared; USPSTF Draft Recs for Osteoporosis; Generic Ozempic in Testing

Abbott announced FDA clearance of two over the counter (OTC) continuous glucose monitoring (CGM) systems: one for adults with type 2 diabetes not on insulin and another for general consumers looking to improve their overall health and wellness.

The FDA slapped a clinical hold on Biomea Fusion’s ongoing mid-stage studies of its investigational covalent menin inhibitor BMF-219 for type 1 and type 2 diabetes for possible drug-induced hepatotoxicity.

The U.S. Preventive Services Task Force (USPSTF) is welcoming public comments on its draft recommendation statement for osteoporosis screening to prevent fractures, which advises that all women 65 and over be screened, along with some younger postmenopausal women with osteoporosis risk factors.

At least 11 generic versions of semaglutide (Ozempic, Wegovy) are in the final clinical trial stages in China. (Reuters)

Former President Donald Trump is taking sole credit for lowering insulin prices, saying President Biden “had nothing to do with it” despite the $35 price cap for Medicare beneficiaries signed into law in 2022 by Biden. (CNBC)

Adding telephone coaching for individuals with a suboptimal response to an online weight-loss program helped patients shed pounds and proved cost-effective. (JAMA Network Open)

In a lawsuit, Roche alleged that counterfeit versions of its Accu-Chek diabetes medical devices ended up on Amazon. (CNBC)

Additional health benefits of weight-loss drugs like semaglutide and tirzepatide (Zepbound) may attract more men to use them, five doctors told Reuters.

Dexcom’s G7 CGM system can now connect directly to the Apple watch.

Amid attacks on in vitro fertilization (IVF), Senate Democrats introduced the Right to IVF Act, comprised of four bills aiming to protect IVF and other assisted reproductive technology. (The Hill)

Female nurses who lived in areas with more aircraft noise (≥55 dB) had 11% higher odds of obesity. (Environment International)

Please enable JavaScript to view the

comments powered by Disqus.